Camille Bargel

It was one and a half years ago.

Actually, we are raising.

We still believe a lot in the company.

We think that we are now in the late seats stage of our company.

We have managed to see that we have the product market fit, but we test a lot of things and we are still finishing our product portfolio.

So now we're raising about roughly $6 to $7 million.

Okay.

Well, we believe that it should be somewhere between 10 to 12 ARR.

Yes.

It's quite simple.

Yes, exactly.

Yeah, we aim to sell 20% at this point and probably do some buyouts of the first initial seed investors so that we don't dilute ourselves.

Well, the R&D center is based in Poland, but the sales offices are based in Munich, Poland, Prague, and Budapest, so a couple of countries.

Well, we are looking at both, basically, because we are also talking with European Investment Bank that has this tool, this venture debt, and we think this could be a potential nice leverage for Series A investors.

So we're also looking at this thing.

No, it's actually European Investment Bank.

No, that's the advantage.

They don't require that.

Well, that's public money, which is backed with this bank.

So they don't simply require it.